Blisovi Fe 1.5/30 Kit
Product Images NDC 68180-869

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Blisovi Fe 1.5/30 (NDC 68180-869). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image-1 (627be501 2e20 4aa0 8fc9 86e3c67250c4 01)

Chemical structure of norethindrone acetate, showing its molecular formula C22H28O3 and molecular weight of 340.46, represented as a structural formula diagram.*

FDA Label Image

Image-2 (627be501 2e20 4aa0 8fc9 86e3c67250c4 02)

Chemical structure of ethinyl estradiol with molecular formula C20H24O2 and molecular weight 296.40, showing the detailed molecular configuration including hydroxyl groups and an alkyne side chain.*

FDA Label Image

Image-3 (627be501 2e20 4aa0 8fc9 86e3c67250c4 03)

A bar chart titled 'Circulatory Disease Mortality Rates per 100,000 Woman Years by Age, Smoking Status and Oral Contraceptive Use' showing mortality rates by age groups 15-24, 25-34, 35-44, and 45 and older. The chart compares four groups: ever-users (non-smokers), ever-users (smokers), controls (non-smokers), and controls (smokers) with different shading patterns representing each.*

FDA Label Image

Image-4 (627be501 2e20 4aa0 8fc9 86e3c67250c4 04)

A forest plot chart comparing effect estimates (relative risk, odds ratio, hazard ratio) from various studies on the use of combined oral contraceptives (COCs). It contrasts 'Ever COC use' versus 'Never COC use' and 'Current COC use' versus 'Never Use' across multiple studies from 2002 to 2017, showing point estimates and confidence intervals on an effect estimate scale.*

FDA Label Image

Image-5 (627be501 2e20 4aa0 8fc9 86e3c67250c4 05)

FDA Label Image

Image-6 (627be501 2e20 4aa0 8fc9 86e3c67250c4 06)

An illustrated dosing schedule guide for BLISOVI FE 1.5/30 oral contraceptive kit showing a four-week layout with days of the week labeled Sunday through Saturday. Circles represent pill positions in each week, with arrows indicating the direction to take pills from left to right each week. Instructions for Day-1 starters and Sunday starters are included, directing where to start taking the pills.*

FDA Label Image

Image-7 (627be501 2e20 4aa0 8fc9 86e3c67250c4 07)

Illustration of a weekly pill-taking chart for BLISOVI FE 1.5/30, showing four weeks labeled Week 1 to Week 4 with days Sunday through Saturday. Arrows indicate the direction to take pills from left to right each week, starting on Sunday for both Sunday starters and Day-1 starters. Instructions advise placing the day label strip that corresponds to the first day of the user's period if it begins on a day other than Sunday.*

FDA Label Image

Image-8 (627be501 2e20 4aa0 8fc9 86e3c67250c4 08)

FDA Label Image

Image-9 (627be501 2e20 4aa0 8fc9 86e3c67250c4 09)

Packaging label for BLISOVI FE 1.5/30 kit containing norethindrone acetate 1.5 mg, ethinyl estradiol 0.03 mg tablets, and ferrous fumarate tablets. The label indicates one blister pack of 28 tablets, distributed by Lupin Pharmaceuticals, Inc. The label includes dosing and storage information, barcodes, and manufacturer details.*

FDA Label Image

Image-10 (627be501 2e20 4aa0 8fc9 86e3c67250c4 10)

Packaging label for BLISOVI FE 1.5/30 oral contraceptive kit by Lupin Pharmaceuticals, Inc. It contains norethindrone acetate 1.5 mg and ethinyl estradiol 0.03 mg tablets, along with ferrous fumarate tablets. The label shows three blisters of 28 tablets each, with prescription-only status. Manufactured by Lupin Limited, India, and distributed in the U.S.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.